Evidence map›Paper›PMID 37881049›Full record

ArticleSkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2023

Effectiveness and safety of Dupilumab for the treatment at 104 weeks of recalcitrant bullous pemphigoid.

Flavia Manzo Margiotta, Cristian Fidanzi, Matteo Bevilacqua, Agata Janowska, Marco Romanelli, Elisabetta Manni

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Successful Use of Dupilumab in Atopic Dermatitis-Like Graft-Versus-Host Disease: A Case Report.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  2. Review
  3. Successful dupilumab treatment in bullous pemphigoid complicated with subacute hematogenous disseminated tuberculosis: A case report.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Flavia Manzo MargiottaDepartment of Dermatology, University of Pisa, Pisa, Italy.
Cristian FidanziDepartment of Dermatology, University of Pisa, Pisa, Italy.
Matteo BevilacquaDepartment of Dermatology, University of Pisa, Pisa, Italy.
Agata JanowskaDepartment of Dermatology, University of Pisa, Pisa, Italy.
Marco RomanelliDepartment of Dermatology, University of Pisa, Pisa, Italy.
Elisabetta ManniDepartment of Dermatology, University of Pisa, Pisa, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Pemphigoid, BullousAntibodies, Monoclonal, HumanizedHumansAntibodies, Monoclonal, Humanizeddupilumab

Identifiers

PMID37881049
PMCPMC10549962

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.